Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024;30(2):531-542. 6. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harbori...
4. Jänne PA, Riely GJ, Gadgeel SM, et al: Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med 387:120-131, 2022 5. Fakih M G, Salvatore L, Esaki T, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C[J...
KRAS mutation in cancer.aThe frequency of KRAS mutations across tumour types, including the mutation frequency of common sites and the subtype with the highest mutation rate in different tumour types. KRAS mutations are characterised by single-base missense mutations, 98% of which are found at codo...
[4] Wei Daoyan, Wang Liang, Zuo Xiangsheng, et al. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin Cancer Res, 2023, undefined: undefined. [5] Prior Ian A, Hood Fiona E, Hartley Jam...
[4] Wei Daoyan, Wang Liang, Zuo Xiangsheng, et al. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin Cancer Res, 2023, undefined: undefined. [5] Prior Ian A, Hood Fiona E, Hartley James L. The Frequency of Ras Mutations in Cancer....
首页/癌基因/KRAS/ MUTATION KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog)基因是GDP/GTP结合蛋白,比较重要的同家族基因还包括HRAS和NRAS。KRAS与GTP结合呈激活状态,与GDP结合呈关闭状态,KRAS可被生长因子或酪氨酸激酶(如EGFR)短暂活化,活化后的KRAS可以激活下游如控制细胞生成的PI3K-AKT-mTOR信号通路,以及控制细...
RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status Coralie Dorard Claire Madry Manuela Baccarini ArticleOpen Access5 Apr 2023 Oncogene Ras protein abundance correlates with Ras isoform mutation patterns in cancer Fiona E. ...
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021). KRAS mutation: from undruggable to druggable in cancer. Signal Transduction and Targeted Therapy, 6(1), 386. https://doi.org/10.1038/s41392-021-00780-4 Jančík, S., Drábek, J., Radzioch, D., & Hajdúch, M. (2010). ...
Fang M. The Research Progress of Direct KRAS G12C Mutation Inhibitors. Pathol, 2021.[5] Tanaka N, Lin JJ, Li C, et al. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer ...
然而，由于KRAS蛋白表面缺乏可供药物结合的口袋，直接针对其突变进行药物靶向治疗一直是个难题。其中，KRAS p.G12C突变体由于其在结构和功能上的特殊性，成为研究的热点和治疗的难点。鉴于此，2023年7月，《Cancers》杂志发表的一篇题为《KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications...